Brian joined LabCorp in September 2017 to serve as Chief Medical Officer for the enterprise. As CMO, he helps drive our company’s clinical strategies around health policy and regulatory efforts, value-based care models and clinical standards of care in our changing health care payment landscape. Prior to joining LabCorp, Brian served a variety of roles at Blue Cross & Blue Shield of North Carolina, including Chief Medical Officer. He was responsible for healthcare program strategy, care management, network provider contracting, medical coverage policy, medical expense initiatives, care quality and pharmacy. Read his full bio.

Interview with Brian Caveney from LabCorp

Q: What need is LabCorp addressing?

A: The timeless issues LabCorp continues to address are those related to delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to improve the delivery of healthcare. Our innovations help to shorten clinical trial times and expand therapeutic options and diagnostics for doctors, positively affecting quality and cost.

Q: What are the products and/or services LabCorp offers/develops to address this need? What makes LabCorp unique?

A: LabCorp understands that one size does not always fit all, as the future of healthcare is personal. By bringing together world-class diagnostics through LabCorp Diagnostics and end-to-end drug development capabilities through Covance Drug Development, LabCorp is uniquely positioned at the intersection of research and patient care to enable more precise and individualized healthcare.

Q: What is your role at LabCorp and what excites you about your work?

A: Every day, I am amazed and impressed by the high level of scientific talent that we have across LabCorp Diagnostics and Covance Drug Development; the level of commitment that employees have to our mission of improving health and improving lives; and our ability to deliver world-class solutions to doctors and patients navigating the increasingly complex healthcare system.

Much of my focus is on our three strategic initiatives: value-based care, consumer engagement and streamlining drug development. LabCorp has chosen to focus on these initiatives because they are the areas where we can bring the most value. More specifically, we are addressing the empowerment of consumers in managing their own healthcare, and exploring how we can use diagnostics to improve healthcare decision-making and control costs. Another area where we can make a big difference is in helping our clients bring medicines to market faster by addressing the time and complexity of clinical trials and patient recruitment.

Q: When thinking about LabCorp and the domain LabCorp is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: LabCorp’s broad portfolio of tests includes many options — from companion diagnostics and pharmacogenetics to genomics and therapeutic drug monitoring — that can help providers identify the right drug, at the right dose, for the right patient.

The majority of drug therapies in development today are driven by biomarkers, or laboratory assays that can indicate whether patients have a particular condition or disease state. These biomarker-driven efforts are what can lead to the development of the appropriate companion diagnostic assays, or in certain situations, a complementary diagnostic. LabCorp is the market leader for the development, validation, and commercialization of companion diagnostics, which are key drivers of personalized medicine.

Additionally, biologics are the fastest-growing drug class and make up more than one-third of the pharmaceutical pipeline. Biologic drugs—which are used to treat many different diseases and conditions, such as Crohn’s disease, rheumatoid arthritis and multiple sclerosis—can not only be expensive, but also highly variable in effectiveness from patient to patient. Therapeutic drug monitoring (TDM) is an area of growth in precision medicine due to increased demand for better treatment outcomes and minimum side effects. TDM is known to promote better patient outcomes and cost savings for payers. One study found a cost savings of 28 to 34 percent through the use of some TDM tests. LabCorp offers the most comprehensive offerings of TDM tests available for many of the highest-grossing prescription drugs on the market.

Q: What are the short-term challenges that LabCorp and its peers are facing?

A: As always, there are a myriad of trends and challenges on the horizon, particularly as our industry experiences rapid changes. As healthcare regulatory and payment systems transform, and the industry experiences cuts to government funding, we continue to innovate our business to address needs for the customer segments we serve across the healthcare continuum, from consumers and physicians to managed care partners and biopharmaceutical companies.

Q: Is there anything else you would like to share with the PMWC audience?

A: Collectively, we need to continue building a solid evidence base for the appropriate use of advanced diagnostics that can help improve clinical outcomes, reduce medication errors, and impact the total cost of care. If we can demonstrate those attributes, precision medicine will flourish in the future.

Interview with Ralph Snyderman from Duke University

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases.

Read More

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

Read More

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe.

Read More

Interview with Rita R. Colwell from University of Maryland College Park and John Hopkins School of Public Health

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: The research that I am focusing on is understanding the microbiome of the human system and the environment, which means understanding the gut flora and its relationship to health and disease.

Read More

Interview with Dr. Nicholas Dracopoli from Personal Genome Diagnostics

Q: What need is Personal Genome Diagnostics (PGDx) addressing?

A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients.

Read More

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome.

Read More

VC Investment in Precision Medicine Boomed in Q2 Mega-deals Hitting Record Levels

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Patrick Conway from Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!